Health Care/Hospital

Head:China makes collaborative efforts in healing people with mental disorders with AI

BEIJING, Nov. 20, 2024 /PRNewswire/ -- After a long day at work, Ni Beiyue sits in front of his computer at home, eagerly immersing himself in the world of creating short videos with AI (artificial intelligence) tools. For nearly three hours, he brainstorms video content, generates mental images ...

2024-11-20 15:13 892

Global Pop Superstar Lisa Teams Up with DENTISTE' Premium Toothpaste to Kick Off Worldwide Oral Care Marketing Campaign

BANGKOK, Nov. 20, 2024 /PRNewswire/ -- Thai-born global superstar Lisa (Lalisa Manobal) of BLACKPINK fame has joined forces with leading premium oral care brand DENTISTE' in a high-profile collaboration destined to make millions smile worldwide.

2024-11-20 13:17 2812

SD Biosensor and the NCCD Discuss Cooperation Measures to Eradicate Infectious Diseases

* A team of officials from the National Center for Communicable Diseases, Mongolia (NCCD), had a tour around the Cheongju and Jeungpyeong Factories of SD Biosensor, aSouth Korea's global in-vitro diagnostics company, during their visit to Korea. * SD Biosensor introduced total diagnostic plat...

2024-11-20 12:44 1040

Neusoft Education Proposes Change of Company Name for Integrated High-Quality Development of Education, Healthcare, Wellness and Travel

HONG KONG, Nov. 20, 2024 /PRNewswire/ -- On November 14, Neusoft Education (09616. HK) announced that the board of directors proposed to change the English name of the Company from"Neusoft Education Technology Co. Limited" to "Neutech Group Limited". According to the announcement, the proposed c...

2024-11-20 11:38 1591

Forging New Paths: Alfasigma Group and Fangzhou Inc. Chart a Course for Internet Healthcare

SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- On November 13th, a high-level delegation from the Alfasigma Group, led by Mr. Andriy Samoylovych, Chief Commercial Officer of Global Growth Markets, and Ms.Zhou Qin, General Manager of Alfasigma China, met with Dr. Xie Fangmin, Chairman and CEO of Fangzhou...

2024-11-20 10:38 1100

Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies

SINGAPORE, Nov. 20, 2024 /PRNewswire/ -- Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, andEdith Cowan University Australia (ECU) today announced a new strategic partnership that aims to enhance clinical ultrasound training for healthcare professio...

2024-11-20 09:00 4457

Samsung Biologics signs manufacturing deal with European pharmaceutical company

* The company will provide manufacturing services through 2031 in deals worth overUSD 668 million * Samsung Biologics' cumulative contract value for 2024 surpasses USD 4 billion with latest deals INCHEON, South Korea, Nov. 20, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global ...

2024-11-20 07:23 1209

Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis B

SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, today announced that it has received approval of clinical trial application (CTA) from the New Zealand Medicines and Medical Devices Safe...

2024-11-20 07:20 1176

Datasea Pre-Announces Full-Year Fiscal 2025 Revenue of $90 Million, Representing a Year-Over-Year Increase of 275%, with Expected Significant Gross Profit Improvement

BEIJING, Nov. 19, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), aNevada-registered digital technology company focused on innovations in acoustic high-tech and 5G AI multimodal digital technologies, today pre-announced that its revenue for the fiscal year ending Jun...

2024-11-19 22:45 1629

Xiao-I Corporation Announces Strategic Cooperation with Deafopia to Expand Market Outreach for AI Hardware Business

SHANGHAI, Nov. 19, 2024 /PRNewswire/ -- Xiao-I Corporation (NASDAQ: AIXI), a leading artificial intelligence company ("Xiao-I") , today announced a strategic cooperation with Deafopia, a nonprofit organization dedicated to supporting businesses within the deaf and hard-of-hearing communities. Thi...

2024-11-19 22:45 1670

Alamar Biosciences Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinson's Research Through Development of Next Generation Biomarker Assays

FREMONT, Calif., Nov. 19, 2024 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic collaboration with The Michael J. Fox Foundation for Parkinson's Research (MJFF) to accelerate biomarker disco...

2024-11-19 22:12 1177

Say Hello to 3.0: Datarithm Releases Latest Version of Inventory Management Solution

SYRACUSE, N.Y., Nov. 19, 2024 /PRNewswire/ -- In a landscape marked by intense competition, rising costs, and stringent regulatory requirements, independent pharmacies face an array of challenges that threaten their viability and success. Today, Datarithm® is proud to announce a solution to these...

2024-11-19 22:00 983

Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS

NANTONG and SUZHOU, China, Nov. 19, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to RAG-21, its novel siR...

2024-11-19 21:26 1035

TRACE International Releases the 2024 Bribery Risk Matrix

ANNAPOLIS, Md., Nov. 19, 2024 /PRNewswire/ -- TRACE, a non-profit international business association dedicated to anti-bribery, compliance, and good governance, has released the 2024 Bribery Risk Matrix, measuring business bribery risk in 194 jurisdictions. Originally published in 2014 to meet a...

2024-11-19 21:00 904

2024 Access to Medicine Index finds that pharma companies are missing opportunities to reach more patients in low- and middle-income countries

AMSTERDAM, Nov. 19, 2024 /PRNewswire/ -- The 2024 Access to Medicine Index finds that pharmaceutical companies are not fully leveraging thei...

2024-11-19 21:00 368

Health2Sync Partners with Singapore Health Promotion Board and Abbott to Launch Innovative DigiCoach Program Tackling Pre-diabetes and Obesity

* "DigiCoach program" is a pilot program by Singapore Health Promotion Board, Health2Sync, and Abbott that aims to help individuals with pre-diabetes or high BMI prevent or delay the onset of diabetes. * Participants can use a continuous glucose monitoring (CGM) device and the Health2Sync mob...

2024-11-19 21:00 1083

Hankyung.com introduces: Unmissable BFCM Deal on Amazon: Get EXTREME DUAL ARGININE PLUS, Free Shipping, and Subscribe & Save Options!

https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image01-1.jpg Photo: 1,000mg x 120 Tablets, 2 Months Supply, Boost up Energy & Vitality for Men's Sports Performance SEOUL, South Korea, Nov. 19, 2024 ...

2024-11-19 21:00 1074

Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

Highlights: * Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) * Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by ~...

2024-11-19 20:30 849

Xinhua Silk Road: Inheriting traditions while promoting innovation, Chinese pharmaceutical company contributes to TCM globalization

BEIJING, Nov. 19, 2024 /PRNewswire/ -- With continuous advancement of the Belt and Road Initiative, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. has been actively promoting the globalization of traditional Chinese medicine (TCM) through both inheriting traditional assets and engaging in mode...

2024-11-19 20:29 3157

Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA

48-week end-of-treatment data from the ongoing Phase 2 ENSURE study clearly demonstrated the added benefits of elebsiran towards achieving a higher functional cure rate in combination with PEG-IFNα Data from multiple combination studies sponsored by the Company and its partner continue to suppor...

2024-11-19 19:30 1575
123456 ... 847